Market capitalization | $533.71m |
Enterprise Value | $1.05b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 7.63 |
EV/Sales (TTM) EV/Sales | 0.94 |
P/S ratio (TTM) P/S ratio | 0.47 |
P/B ratio (TTM) P/B ratio | 1.05 |
Revenue growth (TTM) Revenue growth | 1.93% |
Revenue (TTM) Revenue | $1.13b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Emergent Biosolutions Inc forecast:
3 Analysts have issued a Emergent Biosolutions Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,126 1,126 |
2%
2%
|
|
Gross Profit | 320 320 |
4%
4%
|
|
EBITDA | 25 25 |
145%
145%
|
EBIT (Operating Income) EBIT | -90 -90 |
54%
54%
|
Net Profit | -209 -209 |
74%
74%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | Joseph Papa |
Employees | 1,600 |
Founded | 1998 |
Website | www.emergentbiosolutions.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.